Comparison · NCT00524368-sae
DRV/Rtv 800/100 mg Once Daily vs DRV/Rtv 600/100 mg Twice Daily: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. DRV/Rtv 800/100 mg Once Daily vs DRV/Rtv 600/100 mg Twice Daily: serious adverse events. Trial comparisons, record NCT00524368-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00524368-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0544 | 0.0338 | 0.0866 | wilson | |
| Risk in group 2 | 0.0912 | 0.0634 | 0.129 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0368 | -0.0803 | 0.00568 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.597 | 0.328 | 1.08 | log | |
| Odds ratio, group 1 over group 2 | 0.573 | 0.302 | 1.09 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on DRV/Rtv 800/100 mg Once Daily than on DRV/Rtv 600/100 mg Twice Daily | 27.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | DRV/Rtv 800/100 mg Once Daily | Two 400 mg tablets of darunavir (DRV) + one 100 mg capsule of ritonavir (rtv) once daily | 16 | 294 | EG000 |
| Group 2 | DRV/Rtv 600/100 mg Twice Daily | One 600 mg darunavir (DRV) tablet + one 100 mg capsule of ritonavir (rtv) given twice daily | 27 | 296 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 52 weeks
Source ClinicalTrials.gov
Trial
- Title
- A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)
- NCT number
- NCT00524368
- Phases
- PHASE3
- Conditions
- Human Immunodeficiency Virus - Type 1
- Interventions
- Darunavir (DRV), Ritonavir (rtv)
- Lead sponsor
- Tibotec Pharmaceuticals, Ireland
- Results first posted
- 2010-09-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00524368?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00524368-sae